Skip to main content
. 2020 Dec 1;146(6):e20200395. doi: 10.1542/peds.2020-0395

FIGURE 2.

FIGURE 2

Cost-effectiveness acceptability by willingness to pay. A, Cost per HPV vaccine initiator. B, Cost per cancer case averted. In the figure, we compare 500 simulations of each intervention using net monetary benefit across a range of willingness-to-pay thresholds for each outcome considered.